Skip to main content
AtriCure, Inc. logo

AtriCure, Inc. — Investor Relations & Filings

Ticker · ATRC ISIN · US04963C2098 LEI · 254900B2I6GPHK2EXM59 US Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2020-05-13 Director's Dealing
Country US United States of America
Listing US ATRC

About AtriCure, Inc.

https://www.atricure.com

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling technologies for the treatment of atrial fibrillation (Afib), management of the left atrial appendage (LAA), and post-operative pain. The company's product portfolio is primarily utilized by cardiothoracic surgeons and electrophysiologists. Key offerings include surgical ablation systems and the AtriClip® LAA Exclusion System, a widely implanted device for LAA management. Additionally, AtriCure provides cryoablation technology, such as the cryoXT™ Probe, which offers a non-opioid approach to pain management following surgical procedures, including amputation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-05-13 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. It includes details about the offering size, pricing, underwriters, and intended use of proceeds. There are also references to press releases announcing the offering and its pricing. The document does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is primarily an announcement of a financing event and related agreements. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length (8660 characters) supports it being a substantive filing rather than a brief announcement or certification. Confidence is high given the clear description of a financing transaction and underwriting agreement.
2020-05-13 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a public offering of common stock by AtriCure, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures. The document references registration under the Securities Act of 1933 and includes pricing and underwriting details typical of a securities offering document. This is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to a financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing.
2020-05-13 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by AtriCure, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures. The presence of terms like 'preliminary prospectus supplement', 'offering', 'underwriting discounts and commissions', and references to SEC registration and securities laws clearly indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or a brief summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP.
2020-05-11 English
FORM 4 SUBMISSION
Director's Dealing
2020-05-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a press release announcing clinical trial results, furnished as an exhibit to the Form 8-K. There are no financial statements or detailed financial data included, only a reference to the press release. The document length is 3412 characters, which is relatively short and consistent with an announcement rather than a full report. The content does not match categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is primarily a regulatory filing announcing a press release under Regulation FD. Therefore, the best classification is Regulatory Filings (RNS).
2020-05-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.